BREAST CANCER

A key opinion leader discusses how the role tucatinib is evolving in the management of HER2-positive metastatic breast cancer.

In an interview with Targeted Oncology, Ann H. Partridge, MD, MPH, discussed the response to neoadjuvant chemotherapy among patients with ER-positive, HER2-negative breast cancer and how the 21-gene Breast Recurrence Score aids in the prediction of response for this treatment.

Based on phase 3 findings, F-627 appears at least as efficacious and safe as pegfilgrastim, which is the current standard of care, demonstrating strong and durable benefit in patients with breast cancer.

In an interview with Targeted Oncology, Julie R. Gralow, MD, discussed the findings from the KAITLIN study of T-DM1 in early-stage breast cancer.

“By retrospectively analyzing data from the adjuvant BIG 2-98 trial, we demonstrated that overweight and obese patients treated with a docetaxel-based chemotherapy regimen presented with a worse disease-free and overall survival compared with average weight patients treated with the same chemotherapy regimen."

Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.

"The results of the global phase 3 ASCENT study confirm our initial observations that sacituzumab govitecan has the potential to change the standard management of mTNBC."

In New York City, high cases of COVID-19 continue to be reported with a high prevalence among racial and ethnic minorities.

Sylvia Adams, MD, discusses the synergy between anti-CTLA4 and anti-PD-L1 antibodies as treatment of patients with breast cancer.

Julie Gralow, MD, discusses the use of patient-reported outcomes in the SWOG S1105 trial and different factors for patients with early-stage breast cancer on an aromatase inhibitor to see if they could predict who may be more likely to stop taking treatment early.

IMpassion031, a clinical trial of atezolizumab plus chemotherapy in patients with triple-negative breast cancer, has met its primary end point.

"We can potentially offer a new treatment option for patients with high-risk HR-positive, HER2-negative early breast cancer. "

“With demonstration of efficacy in biomarker-selected BRCA-like phenotype triple-negative breast cancer, the results of this trial are a very positive step toward expanding the role of PARP inhibitors beyond germline BRCA in breast cancer."

Javier Cortes, MD, PhD, discusses the data from the phase 3 KEYNOTE-355 trial of pembrolizumab and chemotherapy versus placebo and chemotherapy for previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast cancer.

"We are disappointed [with] this outcome. Breast cancer is a leading cause of death around the world and delaying or preventing the development of metastatic disease is a significant unmet need. PALLAS is a large study with many subgroups and we are actively collaborating to determine if there are patients who may benefit from adjuvant treatment with the palbociclib combination."

"Pembrolizumab and chemotherapy demonstrated a statistically significant and clinically meaningful improvement in PFS as compared with chemotherapy alone for the first-line treatment of metastatic TNBC with a PD-L1 CPS of 10 or higher tumors."

The addition of tucatinib to treatment with trastuzumab and capecitabine resulted in more than a 60% reduction in the risk of central nervous system progression or death in both patients with previously treated HER2-positive metastatic breast cancer who have active or stable brain metastases.